ONCAlert | Upfront Therapy for mRCC

An Open-Label Extension of SELECT

Lori J. Wirth, MD
Published Online: 4:54 PM, Mon March 9, 2015
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses an open-label extension of the phase III SELECT trial, which looked at lenvatinib versus placebo for the treatment of patients with relapsed/refractory differentiated thyroid cancer.

Clinical Pearls

  • In SELECT, median PFS was 18.3 months with lenvatinib and 3.6 months with placebo.
  • In the open-label extension, PFS was slightly lower (12.4 months). The overall response rate was 54.9%.
  • The best time to initiate treatment in RAI-refractory patients is unknown.

<<< More from the Endo 2015 meeting

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.